- ATX Therapeutics launches to create evidence-based digital therapeutic products to address specific chronic health conditions and associated risk behaviors
- ATX Therapeutics is founded by CEO Adam Falat, who previously led award-winning consumer digital health teams at Walgreens and athenahealth.
Former Walgreens executive Adam Falat today announced the launch of his new Austin-TX-based digital health company, ATX Therapeutics. The new company will create evidence-based digital
Read More
respiratory disease
ResApp Awarded CE Mark for Smartphone-Based Diagnostic Test for Respiratory Disease
ResApp Health, the developers of the world’s first smartphone-based diagnostic test for respiratory disease where one simply coughs into the phone and the machine learning-based algorithm diagnoses the underlying respiratory disease, has received CE Mark certification as a Class IIa medical device.Significance of CE Mark CertificationCE Mark certification indicates that ResAppDx-EU meets the essential requirements of all the applicable European regulations as a medical device and allows for the
Read More
Montefiore Health to Create AI-Based Screening Tool to Help Doctors Identify Lung Failure
Funded by a $1.2 million Agency for Healthcare Research and Quality grant, Montefiore Health System is building a new artificial intelligence (AI) screening tool to help doctors better identify and treat acute respiratory distress syndrome (ARDS), a deadly, but under-recognized, form of lung failure. Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients.The main complication in ARDS is that fluid leaks into the lungs making breathing
Read More
ResApp Licenses New Algorithm to Improve Diagnostic Screening for Childhood Pneumonia
ResApp Health Limited, a digital health startup provider of smartphone apps for respiratory disease diagnosis and management has signed a licensing agreement with UniQuest, the main commercialization company of The University of Queensland. The licensing agreement includes an additional diagnostic toolset of machine-learning algorithms that use a combination of clinical features to screen for childhood pneumonia. Pneumonia is the leading cause of mortality for children below five years of age.
Read More
